Evidence map›Paper›PMID 36333676›Full record

ArticleBMC neurology2022

Collateral status, hyperglycemia, and functional outcome after acute ischemic stroke.

Daniel F Arteaga, Robin Ulep, Kevin K Kumar, Andrew M Southerland, Mark R Conaway, James Faber, Max Wintermark, David Joyner, Vera Sharashidze, Karen Hirsch and 13 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01369069 (Stroke Hyperglycemia Insulin Network Effort), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01369069 phase3completednot on this map

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

TypeinterventionalSponsorUniversity of VirginiaRan2012 to 2018Enrolled1,151ConditionsAcute Ischemic Stroke, Diabetes, HyperglycemiaArmsIV insulin to maintain target glucose concentration of 80-130 mg/dL, Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 1 country.

Daniel F ArteagaDepartment Neurology, St Thomas Rutherford Hospital, Murfreesboro, 1700 Medical Center Pkwy, Murfreesboro, TN, 37129, USA. darteaga08@gmail.com.ORCID http://orcid.org/0000-0002-6690-135X
Robin UlepDepartment of Neurology, Stanford University, Stanford, CA, USA.
Kevin K KumarDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Andrew M SoutherlandDepartment of Neurology, University of Virginia, Charlottesville, VA, USA.
Mark R ConawayDepartment of Statistics, University of Virginia, Charlottesville, VA, USA.
James FaberDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, USA.
Max WintermarkDepartment of Radiology, Stanford University, Stanford, CA, USA.
David JoynerDepartment of Radiology, University of Virginia, Charlottesville, VA, USA.
Vera SharashidzeDepartment of Neurology, Emory University, Atlanta, GA, USA.
Karen HirschDepartment of Neurology, Stanford University, Stanford, CA, USA.
Dan-Victor GiurgiutiuDepartment of Neurology, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Yousef HannawiDepartment of Neurology, The Ohio State University, Columbus, OH, USA.
Yasmin AzizDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Lori ShutterDepartment of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Anita VisweswaranDepartment of Neurology, Stanford University, Stanford, CA, USA.
Alana WilliamsDepartment of Neurology, Emory University, Atlanta, GA, USA.
Kori WilliamsDepartment of Neurology, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Sonya GunterDepartment of Neurology, University of Virginia, Charlottesville, VA, USA.
Heather M HaugheyDepartment of Neurology, University of Virginia, Charlottesville, VA, USA.
Askiel BrunoDepartment of Neurology, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Karen C JohnstonDepartment of Neurology, University of Virginia, Charlottesville, VA, USA.
Vishal N PatelDepartment of Neurology, Emory University, Atlanta, GA, USA.
SHINE Trial Investigators
University of Virginia · USStanford University · USAugusta University · USEmory University · USUniversity of Pittsburgh · USSaint Thomas - Rutherford Hospital · USThe Ohio State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Targeting the Pial Collateral Circulation for Mitigation of Cerebral IschemiaR01NS083633 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZHANG, HUA · 2013 to 2023
$4.5M
NIH HHS NIH-NINDS U01 NS056975NIH HHS NIH-NINDS U01 NS059041NIH HHS NIH-NINDS U01 NS069498NINDS NIH HHS R01 NS083633
6 · The paper itself

Abstract

backgroundMixed data exist regarding the association between hyperglycemia and functional outcome after acute ischemic stroke when accounting for the impact of leptomeningeal collateral flow. We sought to determine whether collateral status modifies the association between treatment group and functional outcome in a subset of patients with large vessel occlusion enrolled in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.

methodsIn this post-hoc analysis, we analyzed patients enrolled into the SHINE trial with anterior circulation large vessel occlusion who underwent imaging with CT angiography prior to glucose control treatment group assignment. The primary analysis assessed the degree to which collateral status modified the effect between treatment group and functional outcome as defined by the 90-day modified Rankin Scale score. Logistic regression was used to model the data, with adjustments made for thrombectomy status, age, post-perfusion thrombolysis in cerebral infarction (TICI) score, tissue plasminogen activator (tPA) use, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Five SHINE trial centers contributed data for this analysis. Statistical significance was defined as a p-value < 0.05.

resultsAmong the 1151 patients in the SHINE trial, 57 with angiographic data were included in this sub-analysis, of whom 19 had poor collaterals and 38 had good collaterals. While collateral status had no effect (p = 0.855) on the association between glucose control treatment group and functional outcome, patients with good collaterals were more likely to have a favorable functional outcome (p = 0.001, OR 5.02; 95% CI 1.37-16.0).

conclusionsIn a post-hoc analysis using a subset of patients with angiographic data enrolled in the SHINE trial, collateral status did not modify the association between glucose control treatment group and functional outcome. However, consistent with prior studies, there was a significant association between good collateral status and favorable outcome in patients with large vessel occlusion stroke.

trial registrationClinicalTrials.gov Identifier is NCT01369069. Registration date is June 8, 2011.

Indexed as

HyperglycemiaIschemic StrokeBlood GlucoseClinical Trials as TopicCollateral CirculationHumansThrombectomyTissue Plasminogen ActivatorTreatment OutcomeBlood GlucoseTissue Plasminogen ActivatorAngiographyDiabetesHyperglycemiaIntracranial collateralsIschemic strokeOutcome

Identifiers

PMID36333676
PMCPMC9635077
OpenAlexW4308354336

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.